Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases-Reference-Cited by-同舟云学术

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Published:2021-05-06 Issue:7 Volume:96 Page:781-789
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Gangat Naseema¹^ORCID,Guglielmelli Paola²^ORCID,Szuber Natasha³,Begna Kebede H.¹^ORCID,Patnaik Mrinal M.¹^ORCID,Litzow Mark R.¹^ORCID,Al‐Kali Aref¹,Foran James M.⁴,Palmer Jeanne M.⁵,Alkhateeb Hassan¹,Elliott Michelle A.¹^ORCID,Hanson Curtis A.⁶,Pardanani Animesh¹^ORCID,Mannelli Francesco²^ORCID,Vannucchi Alessandro M.²^ORCID,Tefferi Ayalew¹^ORCID

Affiliation:

1. Division of Hematology Mayo Clinic Rochester Minnesota USA

2. Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence Florence Italy

3. Department of Hematology Université de Montréal Quebec Canada

4. Division of Hematology Mayo Clinic Jacksonville Florida USA

5. Division of Hematology Mayo Clinic Scottsdale Arizona USA

6. Division of Hematopathology Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26186

Reference28 articles.

1. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups